|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
A qualified SOMAmer-based assay was developed and used for soluble glypican-3 quantification in hepatocellular carcinoma (HCC) patient samples.
|
29605994 |
2018 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
GPC3 has been linked to hepatocellular carcinoma and a few other cancers, however, the mechanistic role of GPC3 in cancer development remains elusive.
|
31428581 |
2019 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In this work, we have developed a SiNPs-based system for the in vitro molecular imaging of hepatocellular carcinoma cells that express high levels of glypican-3 protein (GPC-3) on their surface.
|
28420236 |
2017 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recently, we reported that GPC3-targeted CAR-T cells could eradicate hepatocellular carcinoma (HCC) xenografts in mice.
|
28035433 |
2017 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
By Western blot analysis carried out with a monoclonal anti-GPC3 antibody we generated, the GPC3 protein was found to be overexpressed in 6 hepatoma cell lines, HepG2, Hep3B, HT17, HuH6, HuH7 and PLC/PRF/5, as well as 22 tumors (42.3%).
|
12478660 |
2003 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The conclusion warrants a future study in an HCC population with both high GPC3 expression and high levels of CD16 at baseline to establish codrituzumab's therapeutic benefit in HCC.
|
29535817 |
2018 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
To investigate the role of glypican-3 (GPC3) in cobalt chloride (CoCl<sub>2</sub>)-induced cell apoptosis in hepatocellular carcinoma.
|
31824173 |
2019 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Several recently characterized immunohistochemical markers such as glypican-3 (GPC-3), heat-shock protein-70 (HSP-70), and glutamine synthetase (GS) help distinguish dysplastic nodules from HCC.
|
22914605 |
2013 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
A needle biopsy was immunohistochemically analyzed for Glypican-3, Pan-CK, and CK7 and was confirmed to be metastatic HCC.
|
28279206 |
2017 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Elevation of both OPN and GPC3 may act as an adverse indicator for HBV-related small HCC patients after curative resection.
|
21822558 |
2012 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
A second experiment conducted to compare macrophage infiltration between the xenograft tissues of a GPC3-transfected HCC cell line and its parent GPC3-nonexpressing cell line revealed that the increase in macrophages was stimulated by membrane expression of GPC3.
|
19141032 |
2009 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
All GPC3-CARs rendered T cells highly cytotoxic to GPC3-positive hepatocellular carcinoma, hepatoblastoma, and malignant rhabdoid tumor cell lines in vitro.
|
27530312 |
2017 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We interpret these nodules as neoplastic with most being adenomas (GPC3 negative) that show features of independent origin and represent early stages of carcinogenesis, implying potential to progress to HB or hepatocellular carcinoma.
|
23715166 |
2013 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Taken together, these findings provide insight into the role and mechanism of miR-133b in regulating HCC cell proliferation, invasion and apoptosis via the miR-133b/Sirt1/GPC3/Wnt β-catenin axis, and miR-133b may serve as a potential therapeutic target in HCC in the future.
|
27090017 |
2016 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Glypican-3 (GPC3) is a heparan-sulfate proteoglycan frequently expressed on the cell membrane of malignant hepatocytes in hepatocellular carcinoma.
|
22564378 |
2012 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The results showed that the pooled overall diagnostic sensitivity, specificity, and 95% confidence interval (CI) for serum glypican-3 in the diagnosis of hepatocellular carcinoma were 68% (56-79%) and 92% (82-96.0%), respectively.
|
30071741 |
2018 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma.
|
31142602 |
2019 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In contrast, the groups with HCC subjected to either high or low dose of Ginkgo biloba leaves extract elicited significant reduction (P<0.05) of AFP, CEA and GPC-3 in serum compared to the untreated HCC rats.
|
27741326 |
2017 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study aimed to construct and investigate a new glycosyl-phosphatidylinositol (GPI)-anchored protein (GPC3+alpha+EGFP) as a DNA vaccine against HCC associated with HBV.
|
21459723 |
2011 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
More importantly, immunohistochemical staining demonstrated the inverse correlation between nuclear ZHX2 with GPC3 expression in HCC tissues.
|
25195714 |
2014 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this work, we confirm that RAF1 acts as an oncogene in HCC and further demonstrate that miR-4510 acts as a strong tumour suppressor in the liver by targeting many proto-oncogenes, including GPC3 and RAF1, and subsequently controlling key biological and signalling pathways among which Wnt and RAS/RAF/MEK/ERK signals.
|
31612616 |
2020 |
|
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Codrituzumab, a humanized antibody against glypican-3, is highly expressed in HCC.
|
28120036 |
2017 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus, further preclinical exploration of our modified approach to GPC3-targeted immunotherapy for HCC is warranted.
|
28856237 |
2017 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In South Korean HCC patients, GPC3 expression was more frequent in HCCs with aggressive features, but it was not an independent prognostic biomarker.
|
26764243 |
2016 |
|
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Concomitant use of heat-shock protein 70, glutamine synthetase and glypican-3 is useful in diagnosis of HBV-related hepatocellular carcinoma with higher specificity and sensitivity.
|
29569872 |
2018 |